Survival data were available in 70 cases, and Kaplan–Meier analysis indicated that ESCC patients with high MAP2K3 expression tended to have a better overall survival, which is consistent with the survival data from TCGA (P = 0.11, log‐rank test, Fig. 2G and Fig. S3A, B). The gene discussed is MAP2K3; the disease is esophageal squamous cell carcinoma.